Drugs.com - Clinical Trials

SuperGen to Present Data at the 50th ASH Annual Meeting & Exposition

Tue, 02 Dec 2008 19:40:47 GMT

DUBLIN, Calif., December 02, 2008 /PRNewswire-FirstCall/ -- SuperGen, Inc. , a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced the company's plans to present three posters at the 50th...

GENFIT Therapeutic Potential of GFT505 is Demonstrated in the Treatment of Cardiovascular Risk Associated With Pre-Diabetes

Tue, 02 Dec 2008 15:40:32 GMT

Efficacy data collected on healthy volunteers (GFT505-1084 studies) demonstrate clear beneficial effects of GFT505 on plasma lipids and inflammation markers. The anticipated large efficacy/safety ratio accelerates...

Gemin X Announces Data Presentations for its Novel, Targeted Cancer Therapy Obatoclax at the 50th Annual American Society of Hematology Meeting and Exposition

Tue, 02 Dec 2008 14:50:10 GMT

MALVERN, Pa. & MONTREAL--(BUSINESS WIRE)--Dec 2, 2008 - Gemin X Pharmaceuticals announced today that preclinical data from the company's targeted cancer therapy, obatoclax (GX15-070), an innovative pan-Bcl2 inhibitor, will be presented in three...

Daiichi Sankyo, Inc. Announces Three Studies of Oral Factor Xa Inhibitor DU-176b Accepted for the 50th Annual Meeting of the American Society of Hematology

Tue, 02 Dec 2008 14:35:50 GMT

EDISON, N.J., December 02, 2008 /PRNewswire/ -- Daiichi Sankyo, Inc. , today announced that results from three studies of its investigational molecule, DU-176b, will be presented at the 50th Annual Meeting of the American Society of...

TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia

Tue, 02 Dec 2008 14:25:05 GMT

LA JOLLA, Calif., December 02, 2008 /PRNewswire/ -- TorreyPines Therapeutics, Inc. today announced positive results from a 26 patient Phase II trial evaluating three doses of NGX267 as a treatment for xerostomia, or dry mouth, in patients with...

Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints

Tue, 02 Dec 2008 14:21:00 GMT

Treatment demonstrates significant reduction in the incidence of NSAID-induced upper GI ulcers in patients with mild-to-moderate pain SKOKIE, Ill., December 02, 2008 /PRNewswire/ -- Horizon Therapeutics, Inc., a privately held biopharmaceutical...

Inovio: final melanoma trial results confirm systemic effect and safety

Tue, 02 Dec 2008 13:50:23 GMT

First-Ever Human Trial of DNA-Based Immunotherapy Delivered Using Inovio Biomedical’s Electroporation Technology Shows Safety and Durable Systemic Clinical Response Plasmid IL-12 and Electroporation Combination Against Metastatic...

XenoPort Reports Results from a Phase 2 Clinical Trial of XP19986 as a Treatment for the Symptoms of Gastroesophageal Reflux Disease

Tue, 02 Dec 2008 13:45:03 GMT

XP19986 Monotherapy Generally Well Tolerated and Effective in Reducing Heartburn in GERD Subjects Previously Treated with Proton Pump Inhibitors SANTA CLARA, Calif.--(BUSINESS WIRE)--Dec 2, 2008 - XenoPort, Inc. (Nasdaq:XNPT) announced today...

First-Ever Human Trial of DNA-Based Immunotherapy Delivered Using Inovio Biomedical's Electroporation Technology Shows Safety and Durable Systemic Clinical Response

Tue, 02 Dec 2008 13:40:55 GMT

Plasmid IL-12 and Electroporation Combination Against Metastatic Melanoma Achieves Systemic Response in Untreated Lesions Without Reaching Dose-Limiting Toxicity Pioneering Results Published in Journal of Clinical Oncology SAN DIEGO--(BUSINESS...

Xencor to Present New Data from Pre-Clinical Antibody Programs at Upcoming ASH Conference

Tue, 02 Dec 2008 13:40:17 GMT

MONROVIA, Calif.--(BUSINESS WIRE)--Dec 2, 2008 - Xencor, Inc., a company developing protein and antibody therapeutics, will present new data from its pre-clinical anti-CD19 and anti-CD40 programs, XmAb®5574 and XmAb®5485 respectively, for...

GSK and Theravance Announce Positive Phase 2b Results for LABA, '444 in the Horizon Asthma Development Programme

Tue, 02 Dec 2008 13:30:09 GMT

Initial results demonstrate potential of '444 in the treatment of patients with moderate to severe asthma LONDON, SOUTH SAN FRANCISCO, Dec. 2, 2008-GlaxoSmithKline Plc (GSK) and Theravance, Inc. (NASDAQ: THRX) today announced positive results...

Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet

Tue, 02 Dec 2008 13:10:35 GMT

ROCKVILLE, Md., Dec. 1 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) reports publication in The Lancet, one of the world's leading medical journals, results of clinical trials of its novel circadian regulator, experimental...

TargeGen Affiliates Scheduled for Oral Presentation of Interim Clinical Trial Data at 2008 ASH Meeting in San Francisco for TG101348, a Potent, Selective, Oral JAK2 Inhibitor in Myeloproliferative Disease Patients

Tue, 02 Dec 2008 13:00:06 GMT

SAN DIEGO, December 01, 2008 /PRNewswire/ -- TargeGen has announced that an oral presentation of preliminary results from a multi-center, US-based clinical trial of TG101348 in myeloproliferative disease patients has been scheduled at the 2008...

Experimental TB Drug Explodes Bacteria From The Inside Out

Mon, 01 Dec 2008 22:25:20 GMT

Research Advance May Lead to New Ways to Attack Latent TB and Other Bacteria BETHESDA, Md., Dec. 1, 2008-An international team of biochemists has discovered how an experimental drug unleashes its destructive force inside the bacteria that cause...

Study: Patient Harm More Common with Patient-Controlled Pain Medication

Mon, 01 Dec 2008 20:50:26 GMT

OAKBROOK, Ill., Dec. 1 /PRNewswire-USNewswire/ -- Intravenous patient-controlled analgesia (PCA) allows patients to control their own pain medication, but a new study published in the December 2008 issue of The Joint Commission Journal on Quality...

Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis

Mon, 01 Dec 2008 20:00:32 GMT

Abstinence is still the best policy ROCHESTER, Minn., December 01, 2008 /PRNewswire-USNewswire/ -- A new study from Mayo Clinic finds the use of the drug therapy etanercept ineffective in treating alcoholic hepatitis, an acute inflammation...

Tracking Eye Disorders in Statin Users; Predicting Visual Outcomes for Wounded Soldiers; Improving Glaucoma Tests with Patient Input

Mon, 01 Dec 2008 19:50:47 GMT

Highlights of the December 2008 Issue of “Ophthalmology” SAN FRANCISCO--(BUSINESS WIRE)--Dec 1, 2008 - This month's Ophthalmology, the journal of the American Academy of Ophthalmology, reports on eye disorders that may occur in people...

Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH

Mon, 01 Dec 2008 19:20:42 GMT

SOUTH SAN FRANCISCO, Calif., December 01, 2008 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. , a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics, today announced new data from...

Regulus Therapeutics, Alnylam Pharmaceuticals, and Collaborators Publish First Ever In Vivo Efficacy Data for a microRNA Therapeutic in a Disease Model

Mon, 01 Dec 2008 16:50:15 GMT

– New findings published in the journal Nature demonstrate therapeutic benefit of anti-microRNA-21 in an animal model of heart failure – – Companies to host conference call Monday, December 1, 2008 at 8:30 a.m. ET to discuss...

TorreyPines' NGX426 Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects

Mon, 01 Dec 2008 14:10:53 GMT

LA JOLLA, Calif., December 01, 2008 /PRNewswire/ -- TorreyPines Therapeutics, Inc. today announced that oral administration of NGX426, an AMPA/kainate-type glutamate receptor antagonist, demonstrated a statistically significant reduction in...

Symphogen to Present Positive Preclinical Data on Sym004 Program for EGF-Receptor Positive Cancers

Mon, 01 Dec 2008 13:10:42 GMT

Results will be discussed at the European Antibody Congress in Geneva, December 2 and at IBC's International Conference on Antibody Engineering in San Diego, December 11. COPENHAGEN, Denmark--(BUSINESS WIRE)--Dec 1, 2008 - Symphogen A/S today...

Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call

Mon, 01 Dec 2008 12:55:48 GMT

CARLSBAD, Calif., Dec. 1 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. announces the following webcast: What: New findings published in the journal Nature on the role of a microRNA, known as miR-21, in heart...

Nitric Oxide Can Alter Brain Function

Wed, 26 Nov 2008 19:55:59 GMT

Finding has implications for the treatment of neurodegenerative disease and dementia LEICESTER, England, Nov. 26,2008--Research from the Medical Research Council (MRC) Toxicology Unit at the University of Leicester shows that nitric oxide (NO) can...

Study Compares Strategies for BK Virus Nephropathy

Wed, 26 Nov 2008 19:50:44 GMT

Aggressive Reduction of Immunosuppression Lowers Risk of Kidney Loss in Transplant Recipients WASHINGTON, Nov. 26, 2008 — For kidney transplant recipients with a serious complication called BK virus-associated nephropathy (BKVAN),...

Flamel Technologies Update

Wed, 26 Nov 2008 17:00:38 GMT

CEDEX, France, Nov. 26, 2008-Flamel Technologies has posted an updated presentation on its website. The new presentation accounts for the initiation of an additional feasibility study to evaluate Medusa in conjunction with therapeutic...

Growth hormone not beneficial for ALS

Wed, 26 Nov 2008 15:50:31 GMT

ST. PAUL, Minn., Nov. 24, 2008 – A growth hormone that had shown some promise for treating people with amyotrophic lateral sclerosis (ALS) showed no benefit in a new study published in the November 25, 2008, issue of Neurology, the medical...

Ceregene Announces Clinical Data From Phase 2 Clinical Trial of CERE-120 for Parkinson's Disease

Wed, 26 Nov 2008 15:10:41 GMT

SAN DIEGO, November 26, 2008 /PRNewswire/ -- Ceregene, Inc., a biopharmaceutical company, today reported clinical data from a double-blind, controlled Phase 2 trial of CERE-120 in 58 patients with advanced Parkinson's disease. The trial did not...

Wyeth and Progenics Announce Positive Outcome of Phase 3 Clinical Study of Subcutaneous Relistor for Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain

Wed, 26 Nov 2008 13:45:08 GMT

-- Primary and key secondary efficacy endpoints achieved -- COLLEGEVILLE, Pa. & TARRYTOWN, N.Y.--(BUSINESS WIRE)--Nov 26, 2008 - Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), and Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) announced...

Stanford/Packard Study Shows No Benefit From Drug Widely Used to Prevent Premature Births

Wed, 26 Nov 2008 13:30:16 GMT

STANFORD, Calif.--(BUSINESS WIRE)--Nov 26, 2008 - When a pregnant woman goes into early labor, her obstetrician may give her drugs to quiet the woman's uterus and prevent premature birth. New research shows, however, that one popular drug works no...

Press Release: Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Soft Tissue

Tue, 25 Nov 2008 21:15:54 GMT

SAN MARINO, Calif., Nov. 25, 2008 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies announced today the results of Phase I/II and II studies of Rexin-G in chemotherapy-resistant metastatic soft tissue sarcoma and osteosarcoma, as presented by Dr. Sant...

Telcagepant Proven as a Safe and Effective Migraine Treatment in Phase III Trial

Tue, 25 Nov 2008 17:00:18 GMT

NEW YORK, Nov. 25, 2008-Telcagepant 300 mg is effective as an acute treatment for migraine with efficacy comparable to that of zolmitriptan 5 mg, a widely-used migraine treatment, but with fewer associated adverse effects. These are the conclusions...

Aegera Therapeutics' Phase 1/2 Clinical Trial Results Selected for Oral Presentation at 2008 ASH Annual Meeting

Tue, 25 Nov 2008 15:05:16 GMT

MONTREAL, November 25, 2008 /PRNewswire/ - Aegera Therapeutics Inc. today announced that data from its phase 1/2 clinical trial of the XIAP antisense oligonucleotide, AEG35156, will be highlighted in an oral presentation at the 50th Annual Meeting...

ERYtech Pharma Presents a New Advance in the Treatment of Sickle Cell Anaemia

Tue, 25 Nov 2008 14:55:01 GMT

LYON, France & PHILADELPHIA--(BUSINESS WIRE)--Nov 25, 2008 - ERYtech Pharma has been chosen to present the first pre-clinical results obtained with its product GR-ARA1 on sickle cell anaemia during the 50th annual congress of the American Society of...

Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology

Tue, 25 Nov 2008 14:25:30 GMT

Initial Results from Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Relapsed Multiple Myeloma Featured in Oral Presentations SOUTH SAN FRANCISCO, Calif., November 25, 2008 /PRNewswire/ -- Proteolix, Inc., a leader in the discovery and...

Protox announces positive Phase 2 BPH results

Mon, 24 Nov 2008 21:30:46 GMT

VANCOUVER, Nov. 24 /CNW/ - Protox Therapeutics Inc. (TSX: PRX), a leader in the development of receptor targeted fusion proteins, today announced positive data from its Phase 2 study of PRX302 in patients with benign prostatic hyperplasia (BPH), a...

Schering-Plough Unveils Top-Line Study Results for SAPHRIS (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention

Mon, 24 Nov 2008 20:20:31 GMT

KENILWORTH, N.J., November 24, 2008 /PRNewswire-FirstCall/ -- Schering-Plough Corporation today revealed top-line results of a long-term Phase III clinical study of its psychopharmacologic agent SAPHRIS(TM) (asenapine) demonstrating efficacy...

Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C

Mon, 24 Nov 2008 20:10:46 GMT

Company reaffirms its innovation leadership and long-term commitment to hepatitis research KENILWORTH, N.J., November 24, 2008 /PRNewswire-FirstCall/ -- Schering-Plough Corporation today provided a clinical update on boceprevir, its lead...

Labopharm to Host Webcast Presentation on Novel Trazodone Formulation for Treatment of Major Depressive Disorder

Mon, 24 Nov 2008 19:35:17 GMT

LAVAL, QC, November 24, 2008 /PRNewswire-FirstCall/ - Labopharm Inc. today announced that it will host a webcast presentation on Tuesday, December 16, 2008 at 10:00 am (ET) during which the Company's senior management team will discuss the product...

Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease

Mon, 24 Nov 2008 16:25:39 GMT

KENILWORTH, N.J., November 24, 2008 /PRNewswire-FirstCall/ -- Schering-Plough Corporation today reported that preladenant, its novel and selective adenosine2a receptor antagonist, met the primary endpoint in a Phase II dose-finding trial in patients...

New Cancer Treatment Shrinks Pancreatic Tumor

Mon, 24 Nov 2008 15:55:58 GMT

NASHVILLE, Tenn., November 24, 2008 /PRNewswire/ -- A new cancer treatment is realizing outstanding results against pancreatic cancer. Following five weeks of treatment, a patient's large, stage 4 tumor was reduced in size by 70%. After seven more...